Etanercept treatment in corticosteroid-dependent myasthenia gravis.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 15623708.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The authors report a prospective pilot trial of etanercept in corticosteroid-dependent autoimmune myasthenia gravis. Eleven patients were enrolled, with eight completing the 6-month trial. Two patients were withdrawn owing to disease worsening, and one patient was withdrawn because of an erythematous skin rash. Six of the eight patients who completed the trial improved, based on quantitative measures of muscle strength and lowering of corticosteroid requirement.
Medical subject headings
- Immunoglobulin G
- Myasthenia Gravis
- Receptors, Tumor Necrosis Factor